Jiangsu Jibeier Pharmaceutical Co Ltd (688566) - Total Liabilities
Based on the latest financial reports, Jiangsu Jibeier Pharmaceutical Co Ltd (688566) has total liabilities worth CN¥222.75 Million CNY (≈ $32.60 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 688566 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Jiangsu Jibeier Pharmaceutical Co Ltd - Total Liabilities Trend (2016–2025)
This chart illustrates how Jiangsu Jibeier Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Jiangsu Jibeier Pharmaceutical Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
Jiangsu Jibeier Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangsu Jibeier Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ZheJiang ZhongKe Magnetic Co. Ltd. A
SHE:301141
|
China | CN¥647.16 Million |
|
DL Holdings CO. LTD.
KO:000210
|
Korea | ₩7.16 Trillion |
|
Gokul Agro Resources Limited
NSE:GOKULAGRO
|
India | Rs41.13 Billion |
|
Ronglian Group Ltd
SHE:002642
|
China | CN¥1.39 Billion |
|
Guangdong Vanward New Electric Co Ltd
SHE:002543
|
China | CN¥3.58 Billion |
|
PT Bukalapak.com
JK:BUKA
|
Indonesia | Rp717.57 Billion |
|
Ponsse Oyj 1
HE:PON1V
|
Finland | €218.38 Million |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥397.56 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Jiangsu Jibeier Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Jiangsu Jibeier Pharmaceutical Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Jibeier Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Jibeier Pharmaceutical Co Ltd (2016–2025)
The table below shows the annual total liabilities of Jiangsu Jibeier Pharmaceutical Co Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥267.47 Million ≈ $39.14 Million |
-2.27% |
| 2024-12-31 | CN¥273.68 Million ≈ $40.05 Million |
-8.55% |
| 2023-12-31 | CN¥299.25 Million ≈ $43.79 Million |
+10.73% |
| 2022-12-31 | CN¥270.24 Million ≈ $39.55 Million |
+28.45% |
| 2021-12-31 | CN¥210.40 Million ≈ $30.79 Million |
+23.10% |
| 2020-12-31 | CN¥170.92 Million ≈ $25.01 Million |
+36.56% |
| 2019-12-31 | CN¥125.16 Million ≈ $18.31 Million |
+4.02% |
| 2018-12-31 | CN¥120.32 Million ≈ $17.61 Million |
+38.43% |
| 2017-12-31 | CN¥86.92 Million ≈ $12.72 Million |
-26.96% |
| 2016-12-31 | CN¥118.99 Million ≈ $17.41 Million |
-- |
About Jiangsu Jibeier Pharmaceutical Co Ltd
Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the drug research and development and production in China. The company's products cover multiple therapeutic areas such as increasing white blood cells, fighting hypertension, enhancing immunity, treating joint diseases, fighting eye infections, treating bronchitis, protecting liver function, etc. It is also developing… Read more